Objective-The disease-bearing genes for hypertrophic cardiomyopathy (HCM) in HCM families have been identified as the ,-myosin heavy chain, a-tropomyosin, and cardiac troponin T genes. Three HCM kindreds with three distinct point mutations in the a-tropomyosin gene had extensive clinical evaluations. Design and results-Single-strand conformation polymorphism gel analysis of polymerase chain reaction amplified products was used to capture each of the nine exons from the a-tropomyosin gene to identify mutations in 60 familial HCM patients. Two missense mutations in exon 2 (Ala63Val and Lys7OThr) and one missense mutation in exon 5 (Aspl75Asn)
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were found in three unrelated HCM kindreds. These kindreds were the subject of clinical, electrocardiographic and echocardiographic studies. The morphological appearance of HCM was similar in the three kindreds. All the patients had severe hypertrophy of the left ventricle with asymmetrical septal hypertrophy during the early stage of the disease, which gradually progressed to dilatation of the left ventricle. Moreover, these kindreds showed similar disease penetrance, age of onset, and incidence of premature sudden death. The disease in these kindreds was severe and resulted in frequent sudden deaths. Conclusions-Among Japanese patients with familial HCM mutations in the atropomyosin gene are not as rare as reported, accounting for about 5% of all cases. These mutations are characterised by hypertrophy of the left ventricle which then progresses to dilatation and a high incidence of sudden or disease-related death. 
Patients and methods

CLINICAL STUDIES
Clinical evaluation of family members was performed with the aid of their medical history, a physical examination, a 12 lead electrocardiogram, and a cross sectional echocardiogram. The maximum thickness of the left ventricular wall was measured in diastole in the region of the greatest hypertrophy. A diagnosis of HCM was based on a maximum left ventricular wall thickness of at least 13 mm and absence of the causes of ventricular hypertrophy as specified by Maron's criteria. 9 A venous blood sample for extraction of DNA was obtained after informed consent.
Detection of mutations Screening for mutations was performed with a previously described technique.'0 Individual exons of the a-tropomyosin gene were amplified from genomic DNA by the polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) method.8 The presence of mutations was determined in the PCR-amplified DNA of each individual by cycle sequencing using the Model 373A DNA Sequencing System (Applied Biosystems Japan, Tokyo, Japan).
Mutations are denoted by the normal amino acid residue and its position, followed by the mutant amino acid (for example, Lys7OThr).
Results
The a-tropomyosin sequence was analysed in three probands with HCM who presented different patterns as identified by PCR-SSCP gel analysis. Two of these sequence changes, Three members of family 3, the proband II-6 and his two sisters II-1 and II-3, were diagnosed as having HCM (figure). The most recent echocardiogram of the proband (II-6) and his elder sister (II-1) showed a mildly dilated left ventricle with frequent premature ventricular contractions or episodes of ventricular tachycardia. In 1985, the thicknesses of the proband's interventricular septum and left ventricular wall were 22 mm and 12 mm respectively, but after 10 years of observation they had decreased to 12 mm and 10 mm, respectively. Individual II-3, who showed severe symptoms of congestive heart failure, died suddenly at the age of 50 and was diagnosed post mortem as having dilated-phase HCM. The proband's elder brother also died suddenly at the age of 15, probably from lethal arrhythmia. Both of the proband's parents were dead.
Three members of family 2, the proband II-4, her mother I-2, and her daughter III-1, were diagnosed as HCM (figure). Both individuals II-5 and III-3 died suddenly and the proband also had frequent sustained ventricular tachycardia. The proband was diagnosed by echocardiogram in 1978, when she was 40 years old, as having typical asymmetrical septal hypertrophy. Thereafter, she had symptoms of congestive heart failure with frequent ventricular tachycardia. Her most recent echocardiogram showed a mildly dilated left ventricle. II-5 was admitted to hospital with symptoms of congestive heart failure. Her echocardiogram showed a severely dilated left ventricle and left ventriculography showed an ejection fraction of 21%. A necropsy was not performed and previous echocardiographic data were not available.
Discussion
We have reported a novel mutation in the atropomyosin gene that causes HCM. This mutation, and two previously described mutations,8 characteristically produced moderate hypertrophy that in some instances seemed clinically unimportant. Despite this, the HCM caused by these mutations was associated with a high incidence of sudden or disease-related death. In mutations in cardiac troponin T the severity of cardiac hypertrophy does not reflect the risk of sudden or disease-related death. 7 The two cases reported in this study are particularly good examples of this dissociation: individual II-5 in family 3 and individual III-3 in family 2, both had normal findings on clinical evaluation, but nevertheless died suddenly. Moreover, individuals I-2 and II-3 in family 1, II-1, II-3 and II-6 in family 3, and II-4 and II-5 in family 2 were diagnosed as having dilatedphase HCM ( The similarity between the clinical phenotypes found in conjunction with these atropomyosin mutations is surprising.
Alternatively, the similar results of these mutations may reflect a common intracellular mechanism by which dysfunctional thin filaments trigger cellular hypertrophy.
We found three a-tropomyosin gene mutations in 60 Japanese patients with familial HCM. These mutations were characterised by hypertrophy of the left ventricle which then progressed to the dilated phase and a high incidence of sudden or disease-related death.
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